3 Biotech Stocks With Upcoming Catalysts

Biotech stocks are a sucker for a good catalyst. And they don't care what the overall market is doing when it arrives. Share prices can move north or south in a hurry, with little concern for larger market trends. So it's no wonder that investors tend to pay close attention to clinical and regulatory events for biotechs. With that in mind, here's a look at three biotech stocks with upcoming catalysts that could be major events in the lives of these companies: BioDelivery Sciences International (NASDAQ: BDSI  ) , Pozen Inc. (NASDAQ: POZN  ) , and Keryx Biopharmaceuticals (NASDAQ: KERX  ) . 

BioDelivery Sciences awaits word on its opioid dependence drug
Small-cap biotech BioDelivery Sciences is hoping to have the U.S. Food and Drug Administration approve its New Drug Application, or NDA, for Bunavail by June 7 as a treatment for opioid abuse. The company believes Bunavail could see peak sales of up to $250 million a year as an alternative to Suboxone, a sublingual film consisting of ingredients similar to Bunavil. According to BioDelivery, Suboxone generated over $1 billion in sales in the past year as a treatment for opioid dependence.

What's key to understand is that Bunavil's primary difference is that it's placed inside the cheek instead of under the tongue like Suboxone. And given that Bunavil appears to be a bioequivalent of Suboxone per the clinical data, I don't see this regulatory review as a major hurdle to approval. In light of BioDelivery's tiny market cap of $355 million compared with Bunavil's commercial potential, you may want to get this stock on your watch list.

Keryx hoping for good news for its chronic kidney disease drug
Keryx Biopharmaceuticals also has a June 7 target action date for its drug Zerenex, indicated as a potential treatment for hyperphosphatemia in patients with chronic kidney disease, or CDK. Recently, the European Medicines Agency deemed Zerenex's application in Europe "complete," so it could possibly be approved in both the U.S. and Europe relatively soon. The drug was approved in Japan last January.  

Leading up to this review, Keryx shares have jumped over 75% in the past year, giving the company a market cap of $1.22 billion. That's notable, because the current hyperphosphatemia market is believed to hover around $1 billion a year, and is dominated by Sanofi's (NYSE: SNY  )  sevelamer. Moreover, Impax Laboratories  (NASDAQ: IPXL  ) won the right to market a generic version of sevelamer last year, and the launch of the generic was announced last week. In short, Zerenex will be entering a highly competitive market space, if approved.    

What does this mean for Keryx? My view is that Zerenex will be approved come June, but it's hard to imagine that the drug will become a blockbuster for this initial indication. That said, Zerenex will probably perform well enough to justify the company's present market cap, but Keryx will probably need to secure additional approvals for other indications to push the drug into blockbuster status. Overall, I think most of Zerenex's approval as a treatment for CDK has been baked into the company's present share price.  

Pozen is seeking approval for its aspirin therapies for cardiovascular disease
Pozen is expecting to hear word from the FDA about its aspirin therapies PA8140/PA32540 by April 25. The therapies are designed to reduce gastric ulcers for patients taking aspirin as part of a daily regimen to reduce the risk of cardiovascular disease. Previously, Pozen's therapies were set for FDA review in January, but the date was pushed back to April after the FDA requested a bio-availability study between PA32540 and PA8140. The company announced earlier this month that the study has been finished and submitted to the FDA, completing its NDA. So, without any further delays, we should know the drugs' collective fate this week. 

What's important to know is that Pozen has partnered with Sanofi for these therapies, entitling them to milestone and royalty payments moving forward. Sanofi will be responsible for launching the drugs in the U.S., which could happen as early as the third quarter of this year.

Overall, I'm not concerned as much about the approval of these drugs as I am about what they mean to Pozen's bottom line. The deal it inked with Sanofi won't trigger any milestone payments large enough to be viewed as game-changers -- partly because of the commercial issues with Pozen's other proton pump inhibitor Vimovo. So, you may want to look elsewhere for more profitable catalysts in the biotech arena. 

Foolish wrap-up
Regulatory approvals can send biotech stocks soaring in short order, but you need to keep in mind the value proposition of the drug under review. In the cases of Keryx and Pozen, I don't think much additional value will be created by gaining FDA approval for their products. On the flip side, if the FDA decides to surprise investors with a rejection, these stocks will probably fall hard. By contrast, the market doesn't appear to have noticed the compelling potential value proposition of BioDelivery's Bunavil, making it a stock to watch.  

6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 22, 2014, at 3:22 AM, MudsharkOX wrote:

    You wrote that Impax won the right to market generic sevelamer. That implies that they have an approved ANDA application. In fact, they do not - merely a limited contractual right negotiated with Sanofi.

    Moreover, they have stated on the Q4 2014 earnings call how difficult it was to demonstrate bioequivalence to sevelamer.

    What matters for KERX is the pricing of Renagel and generic competitors (if any). With no current ANDA's publicly approved, that is indeed a risk but also a far lesser risk than your article implies.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2921268, ~/Articles/ArticleHandler.aspx, 8/20/2014 2:55:00 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 5 hours ago Sponsored by:
DOW 16,919.59 80.85 0.48%
S&P 500 1,981.60 9.86 0.50%
NASD 4,527.51 19.20 0.43%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/19/2014 3:59 PM
BDSI $14.01 Up +0.62 +4.63%
BIODELIVERY SCIENC… CAPS Rating: **
IPXL $24.48 Up +0.55 +2.30%
Impax Laboratories… CAPS Rating: **
KERX $16.22 Down -0.30 -1.82%
Keryx Biopharmaceu… CAPS Rating: **
POZN $7.86 Down -0.04 -0.51%
POZEN, Inc. CAPS Rating: **
SNY $53.29 Down -0.15 -0.28%
Sanofi (ADR) CAPS Rating: *****

Advertisement